Published in Biotech Business Week, March 13th, 2006
The TAH-t is the only FDA-approved device capable of providing circulatory restoration in morbidly ill patients with irreversible biventricular failure, bridging them to transplantation when a donor human heart becomes available.
According to Ford, SynCardia will add two hospitals a month to its implant program, making the TAH-t life-saving technology...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.